Neil Aronin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neil Aronin has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
Marian DiFiglia
MassGeneral Institute for Neurodegenerative Disease, 114 16 Street, Charlestown, MA 02129, USA
14 shared publicationsEllen Sapp
MassGeneral Institute for Neurodegenerative Disease, 114 16 Street, Charlestown, MA 02129, USA
12 shared publications- Anastasia Khvorova
RNA Therapeutics Institute, UMass Chan Medical School, Worcester, USA
11 shared publications - Rachael Miller
UMass Chan Medical School, RNA Therapeutics Institute, Worcester, MA 01605, USA
7 shared publications Kathryn Chase
RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01655 , USA
5 shared publicationsMarie-Cecile Didiot
RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA
5 shared publications
Latest Publications
- Open Access
- 15 October 2024
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 35 (4) , 102359
Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation
- 15 October 2024
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 35 (4) , 102359
Open AccessPreventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation
- Open Access
Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation
Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides.
Open AccessPreventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation
Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides.
- Open Access
- 13 October 2022
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 4 (6) , fcac248
Mutant huntingtin messenger RNA forms neuronal nuclear clusters in rodent and human brains
Mutant messenger RNA (mRNA) and protein contribute to the clinical manifestation of many repeat-associated neurological disorders, with the presence of nuclear RNA clusters being a common pathological feature. Yet, investigations into Huntington’s disease—caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene—have primarily focused on toxic protein gain-of-function as the primary disease-causing feature. To date, mutant HTT mRNA has not been identified as an in vivo hallmark of Huntington’s disease. Here, we report that, in two Huntington’s disease mouse models (YAC128 and BACHD-97Q-ΔN17), mutant HTT mRNA is retained in the nucleus. Widespread formation of large mRNA clusters (∼0.6–5 µm3) occurred in 50–75% of striatal and cortical neurons. Cluster formation was independent of age and driven by expanded repeats. Clusters associate with chromosomal transcriptional sites and quantitatively co-localize with the aberrantly processed N-terminal exon 1-intron 1 mRNA isoform, HTT1a. HTT1a mRNA clusters are observed in a subset of neurons from human Huntington’s disease post-mortem brain and are likely caused by somatic expansion of repeats. In YAC128 mice, clusters, but not individual HTT mRNA, are resistant to antisense oligonucleotide treatment. Our findings identify mutant HTT/HTT1a mRNA clustering as an early, robust molecular signature of Huntington’s disease, providing in vivo evidence that Huntington’s disease is a repeat expansion disease with mRNA involvement.
- 13 October 2022
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 4 (6) , fcac248
Open AccessMutant huntingtin messenger RNA forms neuronal nuclear clusters in rodent and human brains
Mutant messenger RNA (mRNA) and protein contribute to the clinical manifestation of many repeat-associated neurological disorders, with the presence of nuclear RNA clusters being a common pathological feature. Yet, investigations into Huntington’s disease—caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene—have primarily focused on toxic protein gain-of-function as the primary disease-causing feature. To date, mutant HTT mRNA has not been identified as an in vivo hallmark of Huntington’s disease. Here, we report that, in two Huntington’s disease mouse models (YAC128 and BACHD-97Q-ΔN17), mutant HTT mRNA is retained in the nucleus. Widespread formation of large mRNA clusters (∼0.6–5 µm3) occurred in 50–75% of striatal and cortical neurons. Cluster formation was independent of age and driven by expanded repeats. Clusters associate with chromosomal transcriptional sites and quantitatively co-localize with the aberrantly processed N-terminal exon 1-intron 1 mRNA isoform, HTT1a. HTT1a mRNA clusters are observed in a subset of neurons from human Huntington’s disease post-mortem brain and are likely caused by somatic expansion of repeats. In YAC128 mice, clusters, but not individual HTT mRNA, are resistant to antisense oligonucleotide treatment. Our findings identify mutant HTT/HTT1a mRNA clustering as an early, robust molecular signature of Huntington’s disease, providing in vivo evidence that Huntington’s disease is a repeat expansion disease with mRNA involvement.
- Open Access
- 22 December 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (24)
Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep
SiRNAs comprise a class of drugs that can be programmed to silence any target gene. Chemical engineering efforts resulted in development of divalent siRNAs (di-siRNAs), which support robust and long-term efficacy in rodent and nonhuman primate brains upon direct cerebrospinal fluid (CSF) administration. Oligonucleotide distribution in the CNS is nonuniform, limiting clinical applications. The contribution of CSF infusion placement and dosing regimen on relative accumulation, specifically in the context of large animals, is not well characterized. To our knowledge, we report the first systemic, comparative study investigating the effects of 3 routes of administration — intrastriatal (i.s.), i.c.v., and intrathecal catheter to the cisterna magna (ITC) — and 2 dosing regimens — single and repetitive via an implanted reservoir device — on di-siRNA distribution and accumulation in the CNS of Dorset sheep. CSF injections (i.c.v. and ITC) resulted in similar distribution and accumulation across brain regions. Repeated dosing increased homogeneity, with greater relative deep brain accumulation. Conversely, i.s. administration supported region-specific delivery. These results suggest that dosing regimen, not CSF infusion placement, may equalize siRNA accumulation and efficacy throughout the brain. These findings inform the planning and execution of preclinical and clinical studies using siRNA therapeutics in the CNS.
- 22 December 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (24)
Open AccessComparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep
SiRNAs comprise a class of drugs that can be programmed to silence any target gene. Chemical engineering efforts resulted in development of divalent siRNAs (di-siRNAs), which support robust and long-term efficacy in rodent and nonhuman primate brains upon direct cerebrospinal fluid (CSF) administration. Oligonucleotide distribution in the CNS is nonuniform, limiting clinical applications. The contribution of CSF infusion placement and dosing regimen on relative accumulation, specifically in the context of large animals, is not well characterized. To our knowledge, we report the first systemic, comparative study investigating the effects of 3 routes of administration — intrastriatal (i.s.), i.c.v., and intrathecal catheter to the cisterna magna (ITC) — and 2 dosing regimens — single and repetitive via an implanted reservoir device — on di-siRNA distribution and accumulation in the CNS of Dorset sheep. CSF injections (i.c.v. and ITC) resulted in similar distribution and accumulation across brain regions. Repeated dosing increased homogeneity, with greater relative deep brain accumulation. Conversely, i.s. administration supported region-specific delivery. These results suggest that dosing regimen, not CSF infusion placement, may equalize siRNA accumulation and efficacy throughout the brain. These findings inform the planning and execution of preclinical and clinical studies using siRNA therapeutics in the CNS.
- 1 October 2020
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 26 (10) , 889-890
Huntington’s Disease: Les Jeux Sont Faits?
- 1 October 2020
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 26 (10) , 889-890
Huntington’s Disease: Les Jeux Sont Faits?
- Open Access
- 1 December 2018
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 11, 65-72
Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer
- 1 December 2018
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 11, 65-72
Open AccessAdeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer
- Top Cited PapersOpen Access
- 1 December 2018
- Published by Elsevier in Molecular Therapy
- Vol. 26 (12) , 2838-2847
Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity
- 1 December 2018
- Published by Elsevier in Molecular Therapy
- Vol. 26 (12) , 2838-2847
Top Cited PapersOpen AccessExosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity
- 24 November 2018
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 7 (4) , 309-319
Selective Neuronal Uptake and Distribution of AAVrh8, AAV9, and AAVrh10 in Sheep After Intra-Striatal Administration
Background: Transgenic sheep are currently the only large animal model of Huntington’s disease expressing full-length mutant human huntingtin. These transgenic sheep provide an opportunity to test adeno associated virus (AAV) therapies directly targe
- 24 November 2018
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 7 (4) , 309-319
Selective Neuronal Uptake and Distribution of AAVrh8, AAV9, and AAVrh10 in Sheep After Intra-Striatal Administration
Background: Transgenic sheep are currently the only large animal model of Huntington’s disease expressing full-length mutant human huntingtin. These transgenic sheep provide an opportunity to test adeno associated virus (AAV) therapies directly targe
- Open Access
- 1 August 2018
- Published by Elsevier in Molecular Therapy
- Vol. 26 (8) , 1973-1982
Optimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles
- 1 August 2018
- Published by Elsevier in Molecular Therapy
- Vol. 26 (8) , 1973-1982
Open AccessOptimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles